SLC3A2 and cancer: In addition, Mao et al.’s data provide compelling evidence that DHODH inhibitors may be used to treat GPX4low cancers; moreover, DHODH inhibitors may be combined with sulfasalazine (an inducer of ferroptosis that inhibits the cystine/glutamate antiporter xCT (SLC7A11/SLC3A2 complex), a component of system xc-) in order to treat GPX4high cancers.